NCT05776134 2026-04-08
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Gilead Sciences
Available
Clinical Trials
8 trialsNCT06553872 2026-03-31
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT02601313 2026-03-18
ZUMA-2
Gilead Sciences
Phase 2 Completed
NCT05495464 2026-02-27
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT06253663 2025-12-16
JKART-1
Gilead Sciences
Phase 2 Active not recruiting
NCT04880434 2025-11-17
ZUMA-2
Gilead Sciences
Phase 2 Completed
NCT06482684 2024-07-01
CARMAN
Ludwig-Maximilians - University of Munich
Phase 2 Recruiting
NCT04162756 2021-10-14
ZUMA-18
Gilead Sciences
Approved for marketing